Drug intelligence / Profile preview

COVA-400

Development stage: Unknown
Lead developer: Silag
Modality: Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics

Overview

COVA-400 is an investigational bispecific protein therapeutic developed by Covagen AG using their Fynomer platform, designed for targeted binding to specific molecular targets in inflammatory or autoimmune diseases. It belongs to a series of COVA compounds, potentially functioning as a dual-targeting agent to modulate immune responses with high specificity and potency. Limited public data exists on its exact mechanism, primary indications, or clinical progress, but it is associated with hemic and lymphatic diseases in pipeline analyses.[8][11][12]

Targets

IL-17A (Interleukin-17A)

Beyond the preview

Go deeper on COVA-400.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on COVA-400.

Explore the full profile